GITR

Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives

Retrieved on: 
Tuesday, March 14, 2023
Society, GITR, Pembrolizumab, BMS, Oncology, ILT2, Standard of care, Infection, NSCLC, Randomness, ASCO, MSS, European Society for Medical Oncology, Colorectal cancer, Doctor of Philosophy, Cancer, Esophageal cancer, Survival rate, Trial of the century, Lung cancer, Head, III, CRC, Quarter, ChromeOS, PD-1, Immunotherapy, Merck, ILT4, Endometrial cancer, American Society of Clinical Oncology, Neck, CD137, SITC, Patient, Society of Gynecologic Oncology, Melanoma, Society for Immunotherapy of Cancer, Safety, ESMO, Gynaecology, Renal cell carcinoma, Sarcoma, The Road Taken, Ovarian cancer, Pharmaceutical industry, Birth control, Medical device, Agenus

"Agenus has entered 2023 with strong momentum across our extensive and diverse clinical pipeline of immuno-oncology programs.

Key Points: 
  • "Agenus has entered 2023 with strong momentum across our extensive and diverse clinical pipeline of immuno-oncology programs.
  • Fourth Quarter and Full Year 2022 Financial Results:
    As of December 31, 2022, we had a cash, cash equivalent and short-term investment balance of $193 million, compared to $218 million and $307 million on September 30, 2022, and December 31, 2021, respectively.
  • For the fourth quarter ended December 31, 2022, we recognized revenue of $28 million and incurred a net loss of $74 million (including non-cash expenses of $33 million) or $0.24 per share.
  • Revenue includes revenue under our collaboration agreements, revenue related to non-cash royalties earned, milestones received, and revenue from Agenus owned CROs.

EQS-News: Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept

Retrieved on: 
Sunday, December 18, 2022
European Medicines Agency, Immunotherapy, CD95L, PRIME, Mortality, CD95, SOC, MDS, Safety, Federation, Cancer, Priority, TNF, GITR, Degenerative disease, Doctor of Philosophy, Immunoglobulin G, TRAIL, Lymphocytopenia, III, AbbVie, Immune system, CD40, COVID-19, Disease, FC, HIV disease progression rates, Standard of care, Microdeletion syndrome, Oxygen, Death, WHO, Ventilation, Glioblastoma, Patient, Pharmaceutical industry, Asunercept, EU

The multicenter, double-blind, placebo-controlled trial aims to enroll more than 600 hospitalized patients requiring oxygen in nine different countries.

Key Points: 
  • The multicenter, double-blind, placebo-controlled trial aims to enroll more than 600 hospitalized patients requiring oxygen in nine different countries.
  • Following the successful controlled ASUNCTIS phase II study, the ASUCOV trial aims to confirm the clinical results in a larger study population.
  • The secondary endpoints of the ASUCOV trial assess the reduction of progression to more severe disease, all-cause mortality, and progression to invasive ventilation.
  • We hope to provide an effective treatment option for hospitalized COVID-19 patients because we still see too many deaths worldwide.

EQS-News: Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients

Retrieved on: 
Saturday, October 22, 2022
Degenerative disease, European Medicines Agency, Immunoglobulin G, Medical University of Vienna, Disease, TRAIL, SOC, AbbVie, PRIME, Critical Care Medicine (journal), Priority, Medical school, Microdeletion syndrome, MDS, Patient, Data monitoring committee, Acute respiratory distress syndrome, DSMB, Standard of care, Federation, Lymphocytopenia, Mortality, II, Cancer, University, CD95, University of Cologne, WHO, TNF, III, Trial of the century, MD, Doctor of Philosophy, COVID-19, FC, Immunotherapy, Safety, GITR, Lymphatic system, Glioblastoma, Death, Pulmonology, Oxygen, CD40, Pharmaceutical industry, Asunercept, EU

Heidelberg, Germany, October 19, 2022 Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial.

Key Points: 
  • Heidelberg, Germany, October 19, 2022 Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial.
  • The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.
  • COVID-19 patients were randomized equally into four study arms, receiving 25, 100, or 400mg asunercept (once weekly, i.v.)
  • The results show strong trends for clinical efficacy in all treatment groups, indicating a robust activity of asunercept.

DGAP-News: Apogenix Receives EUR 20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19

Retrieved on: 
Thursday, December 9, 2021
FC, GITR, BMG, HERA, Interim, CD40, TRAIL, Population, PEI, Investor, CD95, Immunotherapy, BMBF, AbbVie, Disease, Paul Ehrlich Institute, HVEM, CD27, Oxygen, Death, Acute respiratory distress syndrome, TNF, Patient, Acute myeloid leukemia, Asunercept, Lymphatic system, Cancer, II, Vaccination, COVID-19 vaccine, Government, GMP, Education, Priority, European Medicines Agency, COVID-19, MDS, Degenerative disease, Immunoglobulin G, B-cell lymphoma, PRIME, Glioblastoma, Microdeletion syndrome, III, Lymphocytopenia, National Institute of Pharmaceutical Education and Research, Hajipur, Pharmaceutical industry

In addition, the GMP production process for asunercept will be further developed to market maturity and the required material for the phase III clinical trial will be produced.

Key Points: 
  • In addition, the GMP production process for asunercept will be further developed to market maturity and the required material for the phase III clinical trial will be produced.
  • By directly targeting two critical pathogenic mechanisms, asunercept could represent a unique therapeutic approach for the treatment of COVID-19.
  • Apogenix is a private company developing innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19.
  • Asunercept is exclusively licensed to CANbridge Life Sciences under a development and commercialization license covering China, Macao, Hong Kong, and Taiwan.

Therapeutic Solutions International Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in COVID-19 Model

Retrieved on: 
Wednesday, September 22, 2021
Patent, Business development, Clinical trial, Pulmonary fibrosis, TNF, FDA, Patient, CEO, Company, GITR, ELK, OTC Markets Group, COVID-19, Cell, Acceleration, File, B cell, Lung, Radiation-induced lung injury, Pharmaceutical industry

Furthermore, blockade of GITR, a member of the TNF receptor superfamily, resulted in suppression of synergy, suggesting a molecular mechanism of this interaction.

Key Points: 
  • Furthermore, blockade of GITR, a member of the TNF receptor superfamily, resulted in suppression of synergy, suggesting a molecular mechanism of this interaction.
  • "The current discovery provides for novel means of suppressing lung damage, as well as preventing long term-scarring which is a major issue in certain COVID-19 patients."
  • JadiCells, as well as QuadraMune, a commercially available nutraceutical developed by the Company have been shown to reduce lung scarring in other experiments.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.